Josh Jennings
Stock Analyst at Morgan Stanley
(2.62)
# 2,105
Out of 4,900 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $28.93 | +83.20% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $292.01 | +2.74% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $1.82 | +998.90% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $20.50 | +207.32% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $1.06 | +560.38% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $78.28 | -48.90% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $28.93
Upside: +83.20%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $292.01
Upside: +2.74%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $1.82
Upside: +998.90%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $20.50
Upside: +207.32%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $1.06
Upside: +560.38%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $78.28
Upside: -48.90%